Novartis has built up substantial pharmaceutical stockpiles in the United States and announced major manufacturing investments as the Swiss company prepares for potential tariffs under President Trump’s trade policies, CEO Vas Narasimhan revealed on Saturday. Speaking to Swiss newspaper Neue
Merck has officially inaugurated two new facilities in Ireland and Germany as part of its global expansion strategy, representing a combined investment of more than €300 million. In Blarney, Ireland, the company has invested €150 million in a life science
Kindeva has officially opened its expanded metered-dose inhaler (MDI) manufacturing facility at Charnwood Campus in Loughborough, marking an investment in sustainable inhalation therapy manufacturing as the industry transitions toward environmentally-friendly propellants. PharmaSource attended the opening ceremony, which featured a comprehensive
Lilly has announced plans to invest $5 billion to establish a new manufacturing facility west of Richmond, Virginia. The site will be the company’s first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for its bioconjugate platform
GSK announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years. The investment includes a new $1.2 billion commitment to advanced manufacturing facilities and AI and advanced
Life sciences supply chains are moving out of China. This trend briefing, powered by SmartCube, summarises the key points you need to know.
Vertex Pharmaceuticals and Lonza have recently announced a strategic collaboration aimed at supporting the manufacturing of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with Type 1 Diabetes. The 130,000ft² site will be run
Fuliginous Management Consulting regularly tracks the outsourcing activity of 320 pharma companies operating in Europe. In this new research, Kyriakos Kansos reveals some of the key trends in external manufacturing and advises how companies can optimise their pharmaceutical manufacturing network.
The Pharmaceutical Supply Chain Risk Assessment Act is the latest legislation introduced in the US senate to reduce the United States’ dependence on importing drugs from foreign countries. The legislation will have government agencies investigate supply chain weaknesses, siting the
French President Emmanuel Macron has announced plans to bring pharmaceutical production back to France. In a recent speech, he stated that the COVID-19 pandemic has highlighted the need for France to be more self-sufficient in terms of medical supplies. “We
